Vaccine developer Themis pockets Series C funding
Themis, an Austrian vaccine developer, has raised 10 million euros in Series C financing. Global Health Investment Fund was the lead investor with participation from aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences. In addition to the funding, Glenn Rockman, a partner at GHIF, will join Themis’ supervisory board.
4 January 2018•1 min read
